Updated Results of a BTK Degrader for Relapsed CLL – Dr. Stephan Stilgenbauer and Dr. Matthew Davids
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues presented the results at the European Hematology Association (EHA) Annual Meeting in 2026.
